FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
The VPodDuoss (the ‘V’ stands for virus)— can read and compare results from a variety of tests for pathogens or cancer-associated biomarkers.
It’s the brainchild of Lee, University of Illinois Urbana-Champaign Computer Engineering Professor Brian Cunningham, PhD, and Bioengineering Professor Xing Wang, PhD,…
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.
An international study led by Professor Henning Bundgaard, Professor of Cardiology at Rigshospitalet in Copenhagen, Denmark, and Dr Borja Ibáñez, Scientific Director of the Centro Nacional…
Attendees
Sponsors and Exhibitors
Contact us